For your oncology practice to be clinically and financially successful in value-based care, you must be able to measure and manage unwarranted care variability and anticipate risks that could inflate total cost of care. Elsevier’s ClinicalPath (formerly Via Oncology) presents evidence-based oncology pathways embedded in the clinical workflow, and the associated analytics, to help your team make consistent, well-informed decisions for high quality care.

Your ClinicalPath solution

Evidence-based pathways – Deep and broad clinical content, iteratively developed through a consistent, inclusive and transparent process, reflecting the latest evidence and shared best practices of the physicians who use it

Advanced technology – EHR integrated clinical decision support delivered at the point of care, and designed to enhance the clinical workflow

Data insights – Meaningful reporting and analytics to accurately demonstrate your patterns of care

Your ClinicalPath advantage

When you choose ClinicalPath, your organization receives benefits unique to your partnership with Elsevier:

• ClinicalPath exceeds an 80% on-pathway decision rate across medical and radiation oncology pathways
• Proven results and 10+ years of experience working with leading oncology practices
• A growing collaborative network of oncology physicians at the forefront of caring for cancer patients
• Coverage of over 97% of the most common cancer cases in medical and radiation oncology
• Expertise in advanced integration with all major EHRs

• Built-in support to promote clinical trial accrual to advance your research endeavors
• Simplified decisions for using precision medicine with evidence-supported diagnostic testing guidance
• Insight into variations in care patterns and clinical trial accrual performance
• Supporting documents for your oncology care team and patients

Advance your oncology practice with ClinicalPath

ClinicalPath (formerly Via Oncology) won the 2020 MedTech Breakthrough Award for Best Computerized Decision Support Solution for the second consecutive year.
Read this press release

Get started